DIETARY SURVEYS AND NUTRITIONAL EPIDEMIOLOGY

Plasma 25-hydroxyvitamin D3, folate and vitamin B12 biomarkers among international colorectal cancer patients: a pilot study

Cornelia M. Ulrich1,2*, Adetunji T. Toriola3, Erin M. Siegel4, Hermann Brenner5, Jenny Chang-Claude6, Clare Abbenhardt1, Jana Kotzmann1, Xiaoling Song2, Robert W. Owen1, Michael Hoffmeister3, Heiko Becher7, David Shibata4, Kathy Vickers2, Shannon K. Rush2, Karen Makar2, Gerd Würtele1, Roswitha Haubner1, Thomas A. Sellers4 and William Grady on behalf of the ColoCare Consortium2

1Division of Preventive Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
2Fred Hutchinson Cancer Research Center, Seattle, WA, USA
3Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA
4H. Lee Moffitt Cancer Center, Tampa, FL, USA
5Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
6Department of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
7University of Heidelberg, Heidelberg, Germany

(Received 23 March 2012 – Final revision received 14 September 2012 – Accepted 29 October 2012)

Journal of Nutritional Science (2013), vol. 2, e9, page 1 of 6 doi:10.1017/jns.2012.28

Abstract
Vitamin D and folate are associated with decreased colorectal cancer risk and their association with colorectal cancer prognosis is under investigation. We assessed the levels of plasma 25-hydroxyvitamin D3 (25(OH)D3), folate and vitamin B12 in an international pilot study in order to determine variability of these biomarkers based on geographical location. Plasma 25(OH)D3, folate and vitamin B12 concentrations were measured in 149 invasive, newly diagnosed colorectal cancer cases from Heidelberg (Germany), Seattle (WA, USA) and Tampa (FL, USA) and in ninety-one age- and sex-matched controls. Their associations with potential predictors were assessed using multivariate linear regression analyses. Plasma 25(OH)D3 concentrations differed by location. Other predictors were season for 25(OH)D3 and tumour stage (vitamin B12). Season-corrected average 25(OH)D3 concentrations were higher in Heidelberg (31.7 ng/ml; range 11.0–83.0 ng/ml) than in Seattle (23.3 ng/ml; range 4.0–80.0 ng/ml) and Tampa (21.1 ng/ml; range 4.6–51.6 ng/ml). In Heidelberg, a strong seasonal variation was observed. Folate (11.1 ng/ml) and vitamin B12 (395 pg/ml) concentrations in Heidelberg were lower than those in Seattle (25.3 ng/ml and 740 pg/ml, respectively) and Tampa (23.8 ng/ml and 522 pg/ml, respectively). Differences in plasma 25(OH)D3 and folate concentrations between Heidelberg and the US sites were observed, probably reflecting variation in outdoor activities and sun-avoidance behaviour during summer as well as in folic acid fortification and supplement use. Intra-site differences at each study location were greater than between-location variability, suggesting that individual health behaviours play a significant role. Nevertheless, the intra-site differences we observed may be due to chance because of the limited sample size. Our pilot study illustrates the value of an international cohort in studying colorectal cancer prognosis to discern geographical differences in a broad range of exposures.

Key words: Colorectal cancer: Survival: Vitamin D: Vitamin B12: Folate

Vitamin D and folate are critical for cell signalling and functioning and can influence processes related to cancer risk and prognosis(1,2). The anti-carcinogenic effects of vitamin D are mediated through its diverse effects on cellular

Abbreviations: DACHS, Darmkrebs Chancen der Verhütung durch Screening; 25(OH)D3, 25-hydroxyvitamin D3.

* Corresponding author: Cornelia M. Ulrich, email neli.ulrich@nct-heidelberg.de

© The Author(s) 2013. The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercial-ShareAlike licence <http://creativecommons.org/licenses/by-nc-sa/2.5/>. The written permission of Cambridge University Press must be obtained for commercial re-use.
differentiation, proliferation, apoptosis and angiogenesis\(^{(3)}\). Folate and other B vitamins such as vitamin B\(_{12}\) play important roles as co-factors in one-carbon metabolism, which is essential for nucleotide synthesis and DNA methylation\(^{(1,2)}\). Disruption of these processes leads to abnormalities in DNA methylation and imbalance of DNA precursors, leading to aberrant DNA synthesis and repair\(^{(1,2)}\).

Globally, colorectal cancer is the second most commonly diagnosed cancer in women and the third one in men\(^{(4)}\). Studies have demonstrated that a higher pre-diagnostic vitamin D status is associated with a decreased colorectal cancer risk\(^{(5–7)}\), and there is emerging evidence that higher plasma vitamin D concentrations can also improve survival in patients with colorectal cancer\(^{(8,9)}\). On the other hand, folate appears to have a dual effect on colorectal carcinogenesis, depending on the timing and dosage\(^{(10–13)}\). In normal colorectal epithelial cells, folate deficiency predisposes to colorectal carcinogenesis whereas in established neoplasms, folate deficiency appears to have an inhibitory effect on colorectal carcinogenesis and high folate levels may promote the growth of an existing cancer\(^{(15,16)}\). Vitamin B\(_{12}\) is an important co-factor in folate metabolism but studies relating plasma vitamin B\(_{12}\) to colorectal cancer risk and prognosis are relatively very few and results equivocal\(^{(15,16)}\). Because there is paucity of information on how these nutritional biomarkers impact on colorectal cancer survival, more studies are needed to discern their effects.

Plasma vitamin biomarker levels may vary based on dietary and other health-related practices in different countries. However, studies comparing this wide range of vitamin biomarker levels across geographical regions are scarce. A characterisation of this variability may be important for studying the association of these biomarkers with colorectal cancer prognosis. In order to discern geographical differences in plasma 25-hydroxyvitamin D\(_3\) (25(OH)D\(_3\)), folate and vitamin B\(_{12}\), we evaluated levels and predictors among colorectal cancer cases and controls in an international pilot study with participants from Heidelberg (Germany), Seattle (WA, USA), and Tampa (FL, USA).

**Methods**

**Study groups**

The study participants from the USA are members of a colorectal cancer prognosis study (ColoCare), with sites at the Fred Hutchinson Cancer Research Center, Seattle (WA, USA), H. Lee Moffitt Cancer Center and Research Institute, Tampa (FL, USA), and the National Center for Tumor Diseases, German Cancer Research Center, Heidelberg (Germany). The objective of our consortium is to identify the factors that determine short-term survival in a prospective cohort of colorectal cancer patients. These include inherited genetic and tumour characteristics that affect early detection, treatment response and prognosis as well as health behaviours that patients adopt that may have health outcomes. German samples included in this pilot study were obtained from participants in a screening and surveillance colonoscopy programme who had no evidence of pathology within the colon and were matched to the cases for age, sex and race. This study was conducted according to the guidelines laid down by the Declaration of Helsinki and all procedures involving human subjects were approved by the Institutional Review Boards of the German Cancer Research Center (DKFZ), the Fred Hutchinson Cancer Research Center, Seattle (WA, USA) and H. Lee Moffitt Cancer Center and Research Institute, Tampa (FL, USA). Written informed consent was obtained from all the subjects.

**Laboratory analysis**

Plasma 25(OH)D\(_3\) was measured by reverse-phase HPLC in the Biochemistry and Biomarkers Laboratory of the Division of Preventive Oncology, German Cancer Research Center, DKFZ (Dr Owen). The intra-assay and inter-assay CV of 25(OH)D\(_3\) at a concentration of 50 ng/ml were 2.3 and 3.1 %, respectively. Plasma folate and vitamin B\(_{12}\) were quantified using SimulTRAC\textsuperscript{®} B\(_{12}\)/FOLATE – SNB 57Co/\textsuperscript{125}I Radioassay Kit (MP Biomedicals) in the Biomarker Laboratory (Dr Song) at the Fred Hutchinson Cancer Research Center with intra-assay CV of 3-1 and 3.5 % and inter-assay CV of 7-0 and 5.1 % for folate and vitamin B\(_{12}\), respectively.

**Statistical analysis**

To account for skewed distributions, Wilcoxon or Kruskal–Wallis tests were used to test for the differences in biomarker concentration by age group (18–59, 60–69 and 70–80 years),
Results

Cases and controls were, on average, aged 60·0 (sd 13·3) and 60·9 (sd 13·1) years, respectively. The majority of tumours were of stages III (39·6 %) and IV (26·2 %). Among the cases, the mean 25(OH)D3, folate and vitamin B12 concentrations were 25·6 (sd 13·5) ng/ml, 21·6 (sd 14·0) ng/ml, and 638 (sd 597) pg/ml, respectively, whereas among the controls, they were 25·9 (sd 14·0) ng/ml, 18·0 (sd 13·7) ng/ml, and 515 (sd 241) pg/ml (Table 1).

In multivariate modelling, significant predictors for the biomarkers included season for 25(OH)D3, study site for 25(OH)D3, folate, vitamin B12, and tumour stage for vitamin B12 (Table 2). Probably because of the limited sample size of this pilot study, case status was not statistically significant as a predictor; hence, cases and controls were combined in subsequent analyses. Also, the results from models excluding case-status were identical to those including case-status in the model. The association from controls only was similar, a predictor; hence, cases and controls were combined in subsequent analyses. Also, the results from models excluding case-status were identical to those including case-status in the model.

Discussion

To the best of our knowledge, this is the first study to compare a range of nutritional biomarkers (25(OH)D3, folate and vitamin B12) among colorectal cancer patients and controls in different geographical regions. Our international pilot study...

Table 1. Baseline characteristics of colorectal cancer cases and controls

| Characteristic | Cases (n 149) | Controls (n 91) |
|---------------|--------------|----------------|
| Study site    |              |                |
| Heidelberg    | 40 26·8      | 40 44·0        |
| Seattle       | 91 61·1      | 33 36·3        |
| Tampa         | 18 12·1      | 18 19·8        |
| Age (years)   |              |                |
| Mean          | 60           | 61             |
| SD            | 13           | 13             |
| 18–59         | 64 43        | 36 40          |
| 60–69         | 47 32        | 32 35          |
| 70–90         | 38 26        | 23 25          |
| Sex           |              |                |
| Male          | 80 54        | 48 53          |
| Female        | 69 46        | 43 47          |
| Race          |              |                |
| White, non-Hispanic | 137 92 | 84 92        |
| Non-white or other | 12 8 | 7 8          |
| Tumour stage  |              |                |
| I (I, IA, IB and IC) | 20 13·4 | – –          |
| II (II, IIA, IIB and IIC) | 30 20·1 | – –          |
| III (III, IIIA, IIB and IIIC) | 59 39·6 | – –          |
| IV            | 39 26·2      | – –            |
| Unknown       | 1 0·7        | – –            |
| Season of blood draw |          |                |
| Spring (March–May) | 27 18·1 | 23 25·3      |
| Summer (June–August) | 32 21·5 | 25 27·5      |
| Autumn (September–November) | 44 29·5 | 23 25·3      |
| Winter (December–February) | 46 30·9 | 20 22·0      |
| Nutritional biomarker |          |                |
| 25(OH)D3 (ng/ml) |          |                |
| Mean          | 25·6         | 25·9           |
| SD            | 13·5         | 14·0           |
| Range         | 4·6–80·0     | 4·0–83·0       |
| Folate (ng/ml) |          |                |
| Mean          | 21·6         | 18·0           |
| SD            | 14·0         | 13·7           |
| Range         | 0·3–70·3     | 1·4–62·5       |
| Vitamin B12 (pg/ml) |      |                |
| Mean          | 638          | 515            |
| SD            | 507          | 241            |
| Range         | 96–3750      | 94–1352        |

25(OH)D3, 25-hydroxyvitamin D3.

Table 2. Predictors of plasma 25-hydroxyvitamin D3 (25(OH)D3), vitamin B12 and folate among colorectal cancer cases and controls

| Biomarker | Predictor   | Direction | Significance |
|-----------|-------------|-----------|--------------|
| 25(OH)D3  | Heidelberg  | +         | **           |
| Summer season | +         | **         |
| Autumn season | +         | *           |
| Vitamin B12 | Heidelberg | –         | **           |
| Stage IV   | +          | **         |
| Folate     | Heidelberg  | –         | **           |
| Age 60–69 years | +         | *           |

* P < 0·01, ** P < 0·05.
† Cases and controls were combined because case status was not statistically significant.
revealed differences in biomarker concentrations between the US sites and Germany.

Because dietary sources of vitamin D are very limited, cutaneous synthesis of vitamin D (within the UVB wavelength of 290–315 nm) is a very important source of plasma 25(OH)D₃ (19). The UV radiation required for the synthesis of vitamin D in the skin is more abundant and more functional during summer than during winter (19,20). Hence, among people who do not use adequate vitamin D supplements or consume vitamin D-fortified foods, season is one of the most important determinants of plasma 25(OH)D₃ concentrations.

Thus, the seasonal variations in plasma 25(OH)D₃ observed in Heidelberg are in line with expectations. Somewhat surprising is the lack of seasonal variation and the low plasma 25(OH)D₃ concentrations observed in Seattle and Tampa. Of the three sites, Tampa has the highest daytime temperatures during summer but the participants from Tampa had the lowest plasma 25(OH)D₃ concentrations during summer. The differences in plasma 25(OH)D₃ concentration during summer among participants in our study could reflect the extent of outdoor activities and possible sun-avoidance behaviours (including sunscreen use) in the three cities. In Heidelberg, people are more likely to commute with bicycles or walk than use cars, whereas people are more likely to practise sun-avoidance in Florida (21).

Few studies have examined the impact of season on 25(OH)D₃ concentrations in lower altitude regions in the USA. Although a previous study in South Florida reported a seasonal variation in serum 25(OH)D₃ concentrations (21), the

| Table 3. Nutritional biomarker concentrations among colorectal cancer cases and controls in the three study locations (Mean values and ranges) |
|---------------------------------|---------------------|---------------------|---------------------|
|                                | Heidelberg          | Seattle             | Tampa               |
|                                | Mean | Range          | Mean | Range          | Mean | Range          |
| 25(OH)D₃ (ng/ml)               | 31.7 | 11.0–83.0      | 23.3 | 4.0–80.0       | 21.1 | 4.6–51.6      |
| Folate (ng/ml)                 | 11.1 | 0.3–48.2       | 25.3 | 3.5–70.3       | 23.8 | 6.8–69.7      |
| Vitamin B₁₂ (pg/ml)            | 395  | 96–1641        | 740  | 183–3750       | 522  | 94–1085       |

25(OH)D₃: 25-hydroxyvitamin D₃.

Fig. 1. (a) Plasma vitamin D (25-hydroxyvitamin D; 25(OH)D) concentration by study site. (b) Plasma folate concentration by study site. (c) Plasma vitamin B₁₂ concentration by study site. The horizontal bars represent medians and the circles represent potential outliers in the data. (d) Seasonal plasma 25(OH)D by study site: ☀ spring; ☀ summer; ☀ autumn; ☀ winter. Values are means.
magnitude (14 %) is much smaller than what is observed (38 %) among residents of northern latitudes in the USA\textsuperscript{21,22}. Compared with the previous study from South Florida, the winter 25(OH)D\textsubscript{3} concentrations among participants from Tampa in our study are identical (23.3 ± 23.1 ng/ml, respectively) but the summer concentrations were lower (17.7 ± 26.8 ng/ml). Thus, the low summer 25(OH)D\textsubscript{3} concentrations in Tampa could be a chance finding due to the low number of participants from Tampa in our study.

Studies have revealed that current food fortification practices in the USA may not be adequate to prevent vitamin D deficiency among vulnerable people during winter\textsuperscript{23,24}. Likewise, it has been shown that although supplement use increases serum 25(OH)D\textsubscript{3} concentrations, it does not make up for insufficient sun exposure\textsuperscript{25}, and current supplement recommendations are not adequate to prevent vitamin D deficiencies\textsuperscript{26}. As vitamin D supplementation is discussed in the context of improving survival in colorectal cancer patients\textsuperscript{8,20}, our study shows that high plasma vitamin D concentrations can be achieved in populations with substantial outdoor activity during summer (such as Heidelberg). Nevertheless, vitamin D fortification in the USA did not prevent low levels of serum 25(OH)D\textsubscript{3} in Tampa or Seattle, cities that practise sun-avoidance or reduced sun exposure.

The lower plasma folate concentrations among participants from Heidelberg compared with those from the USA are not unexpected considering the fact that mandatory fortification of staple foods with folic acid commenced in the USA in 1998\textsuperscript{27} while fortification is not practised in Germany\textsuperscript{28}. The mandatory fortification programme has resulted in a substantial increase in plasma folate concentrations in the USA, where the prevalence estimates for low serum folate concentrations (<3 ng/ml) declined from 20.6 % in the period 1988–1994 to 0.6 % in 2004\textsuperscript{29}.

However, we also observed large intra-site differences in plasma folate and vitamin B\textsubscript{12} concentrations at each study site. This may be due mostly to the use of folic acid-containing supplements. It has been shown that supplement and multivitamin use is higher among cancer patients compared with the general population\textsuperscript{30}. Between 64 and 81 % of cancer patients use any vitamin or mineral supplement, compared with 50 % in the general population\textsuperscript{31}. In a large study in Washington state, USA, colorectal cancer patients were 33 % more likely to use folic acid supplements compared with cancer-free controls\textsuperscript{31} and such a supplement use is associated with higher plasma folate and vitamin B\textsubscript{12} concentrations\textsuperscript{32}. Therefore, the use of folic acid-containing supplements is an important determinant of plasma folate concentrations in colorectal cancer patients. This may be of potential concern considering the fact that very high plasma folate concentrations that can be achieved with supplement use may accelerate the growth of already existing colorectal cancers\textsuperscript{10}. In a randomised controlled trial, folic acid given at a dosage of 1 mg/d was associated with a 1.7-fold increased risk of advanced colorectal cancers\textsuperscript{12}, thus excluding its utility and safety as a secondary or tertiary prevention agent for colorectal cancer. However, this is an area of ongoing research and further studies are needed to elucidate the relationship between folate and survival in patients with colorectal cancer.

A particular strength of our study is the comparison of biomarkers across international study sites with identical laboratories for assays and consistent blood-draw protocols. However, our sample size as well as variable set was limited and we had no information on supplement use; hence we could not investigate the association of supplement use with nutritional biomarker concentrations.

In conclusion, we observed substantial differences in nutritional biomarker concentrations across international study sites, probably reflecting dissimilarities in supplement use, food fortification, and sun-seeking behaviour, among other health practices. However, intra-site differences at each study location were larger than between-location variability, suggesting that individual health behaviours play a significant role. As we aim to understand predictors of colorectal cancer prognosis, there is much to learn from international cohorts, which offer a broad range of exposure and health behaviours that cannot be obtained at a single site.

Acknowledgements

We thank all the participants of the DACHS study and the interviewers, physicians and recruiting hospitals who have been involved in the study. We also acknowledge the excellent technical assistance rendered by Ute Handte-Daub, Renate Hettler-Jensen, Belinda Su Kapereit and Muhabbet Celik.

The DACHS study was supported by grants from the German Research Council (Deutsche Forschungsgemeinschaft, grant numbers BR 1704/6-1, BR 1704/6-3, BR 1704/6-4 and CH 390 117/1-1), and the German Federal Ministry of Education and Research (grant numbers 01KH0404 and 01ER0814).

The study was conceived of and designed by C. M. U., E. S., H. B., J. C. C., C. A., M. H., K. M., T. A. S. and W. G. Funding was obtained by C. M. U., E. S., H. B., J. C. C., D. S., K. M., T. A. S. and W. G. Data were acquired by C. M. U., E. S., H. B., J. C. C., C. A., X. S., R. W. O., M. H., D. S., K. V., S. K. R., G. W. and R. H. In charge of quality control of data and algorithms were H. B., J. C. C., C. A., X. S., R. W. O., M. H., K. V., S. K. R., G. W. and R. H. Data analysis and interpretation were performed by C. M. U., A. T. T., E. S., H. B., J. C. C., M. H., H. B., K. M., T. A. S. and W. G. Statistical analysis was done by J. K. and H. B. The manuscript was prepared by A. T. T., C. A., J. K. and S. K. R. The manuscript was reviewed by T. A. S. and W. G. The manuscript was edited by C. M. U., E. S., H. B., J. C. C., X. S., R. W. O., M. H., K. M., T. A. S. and W. G. and R. H. Data analysis and interpretation were performed by C. M. U., A. T. T., E. S., H. B., J. C. C., M. H., H. B., K. M., T. A. S. and W. G. Statistical analysis was done by J. K. and H. B. The manuscript was prepared by A. T. T., C. A., J. K. and S. K. R. The manuscript was edited by C. M. U., E. S., X. S., M. H., H. B., D. S., K. V., K. M., T. A. S. and W. G. The manuscript was reviewed by C. M. U., E. S., H. B., J. C. C., R. W. O., G. W. and R. H.

There is no conflict of interest.

References

1. Ulrich CM (2005) Nutrigenetics in cancer research – folate metabolism and colorectal cancer. J Natl Cancer Inst 135, 2698–2702.
2. Lamprechts SA & Lipkin M (2003) Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer 3, 601–614.
3. Deeb KK, Trump DI, & Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7, 684–700.

4. Jemal A, Bray F, Center MM, et al. (2011) Global cancer statistics. CA Cancer J Clin 61, 69–90.

5. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. (2010) Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case–control study. Br Med J 340, b5500.

6. Gandini S, Boniol M, Haukka J, et al. (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128, 1414–1424.

7. Yin L, Grandi N, Baum E, et al. (2009) Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 30, 113–125.

8. Ng K, Meyerhardt JA, Wu K, et al. (2008) Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J Clin Oncol 26, 2984–2991.

9. Ng K, Sargent DJ, Goldberg RM, et al. (2011) Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol 29, 1599–1606.

10. Kim YI (2006) Folate: a magic bullet or a double edged sword. J Cancer Res 90, 116–123.

11. Kim S, Medline A, Mason JB, et al. (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 60, 5434–5440.

12. Ulrich CM & Potter JD (2006) Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 15, 189–193.

13. Cole BF, Baron JA, Sandler RS, et al. (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Assoc 297, 2351–2359.

14. Song J, Madline A, Mason JB, et al. (2000) Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res 60, 5434–5440.

15. Ulrich CM & Potter JD (2007) Folate and cancer – timing is everything. J Am Med Assoc 297, 2408–2409.

16. Dahlin AM, Van Guelpen B, Hultdin J, et al. (2008) Plasma vitamin B12 concentrations and the risk of colorectal cancer: a nested case–referent study. Int J Cancer 122, 2057–2061.

17. Eussen SJ, Vollset SE, Hustad S, et al. (2010) Plasma vitamins B2, B6, and B12, and related genetic variants as predictors of colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 19, 2549–2561.

18. Brenner H, Chang-Claude J, Seller CM, et al. (2011) Protection from colorectal cancer after colonoscopy: a population-based, case–control study. Ann Intern Med 154, 22–30.